JCM
TVTX icon

Jafra Capital Management’s Travere Therapeutics TVTX Stock Holding History

Jafra Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,226
Closed -$329K – 109
2017
Q3 		$329K Buy
13,226
+55
+0.4% +$1.21K 0.12% 68
2017
Q2 		$255K Sell
13,171
-1,829
-12% -$33.2K 0.09% 71
2017
Q1 		$277K Buy
+15,000
New +$293K 0.11% 61

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jafra Capital Management's TVTX Position: Q4 2017 in Review

Jafra Capital Management sold out of Travere Therapeutics (TVTX) in Q4 2017, closing a stake of 13,226 shares — an estimated $329K sold.

Jafra Capital Management first reported a position in TVTX in Q1 2017 and held it in 3 quarters. The position peaked at $329K in Q3 2017. 120 funds tracked by Wall St. Rank hold TVTX as of Q4 2017.

  • Jafra Capital Management reported no remaining Travere Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Jafra Capital Management sold 13,226 Travere Therapeutics shares in Q4 2017, an estimated $329K.
  • Jafra Capital Management first reported a position in Travere Therapeutics in Q1 2017 and held it in 3 quarters.
  • Jafra Capital Management's Travere Therapeutics position peaked at $329K in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2017.

Based on Jafra Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.